CBIO - Catalyst Biosciences Inc Stock Price, Fair Value and News

$13.33+0.24 (+1.83%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CBIO Price Action

Last 7 days

-11.6%

Last 30 days

7.9%

Last 90 days

-2.6%

Trailing 12 Months

-22.5%

CBIO RSI Chart

CBIO Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

108.55

Price/Sales (Trailing)

11.97

EV/EBITDA

70.83

Price/Free Cashflow

437.22

CBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CBIO Fundamentals

CBIO Revenue

Revenue (TTM)

107.3M

Rev. Growth (Yr)

-18.82%

Rev. Growth (Qtr)

-20.86%

CBIO Earnings

Earnings (TTM)

11.8M

Earnings Growth (Yr)

107.84%

Earnings Growth (Qtr)

276.65%

CBIO Profitability

EBT Margin

14.24%

Return on Equity

8.61%

Return on Assets

7.42%

Free Cashflow Yield

0.23%

CBIO Investor Care

Dividend Yield

182.79%

Dividend/Share (TTM)

Shares Dilution (1Y)

6.13%

Diluted EPS (TTM)

0.53

CBIO Alerts

Big jump in Earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	100.6M	102.2M	107.3M	0
2024	115.7M	111.6M	105.0M	105.8M
2023	105.1M	107.9M	110.7M	113.5M
2022	54.8M	0	0	102.3M
2021	6.0M	5.5M	6.9M	7.3M
2020	9.0M	13.0M	17.0M	20.9M
2018	5.0M	0	0	0
2017	560.5K	562.5K	771.5K	1.0M
2016	1.2M	436.0K	436.0K	398.5K
2015	2.2M	2.8M	2.3M	1.7M
2014	845.5K	1.2M	1.5M	1.8M
2013	38.5M	4.9M	4.1M	523.0K
2012	81.5M	94.4M	76.2M	57.9M
2011	105.2M	105.0M	102.2M	97.6M
2010	0	45.3M	65.5M	85.7M
2009	0	0	0	25.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Catalyst Biosciences Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CEO	Dr. Nassim Usman Ph.D.
WEBSITE	catalystbiosciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	7

Catalyst Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Catalyst Biosciences Inc? What does CBIO stand for in stocks?

CBIO is the stock ticker symbol of Catalyst Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalyst Biosciences Inc (CBIO)?

As of Wed Dec 03 2025, market cap of Catalyst Biosciences Inc is 1.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CBIO stock?

You can check CBIO's fair value in chart for subscribers.

Is Catalyst Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CBIO is over valued or under valued. Whether Catalyst Biosciences Inc is cheap or expensive depends on the assumptions which impact Catalyst Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CBIO.

What is Catalyst Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, CBIO's PE ratio (Price to Earnings) is 108.55 and Price to Sales (PS) ratio is 11.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CBIO PE ratio will change depending on the future growth rate expectations of investors.